Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer
- 15 July 1980
- Vol. 46 (2) , 253-255
- https://doi.org/10.1002/1097-0142(19800715)46:2<253::aid-cncr2820460205>3.0.co;2-1
Abstract
The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.This publication has 15 references indexed in Scilit:
- Mammary Tumour Inhibition and Subacute Toxicity in Rats of Prednimustine and of Its Molecular Components Chlorambucil and PrednisoloneActa Pharmacologica et Toxicologica, 1978
- Continuous Treatment of Non-Hodgkin’s Malignant Lymphoma with Prednimustine (Leo 1031)Oncology, 1978
- Leo 1031 (NSC-134087) in Gynecologic MalignanciesOncology, 1978
- Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucilPublished by Elsevier ,1977
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1977
- Integration of chemotherapy into combined modality treatment of solid tumors: VII. Adenocarcinoma of the breastCancer Treatment Reviews, 1976
- Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinomaPublished by Elsevier ,1975
- THERAPEUTIC EFFECT OF LEO 1031, AN ALKYLATING CORTICOSTEROID ESTER, IN LYMPHOPROLIFERATIVE DISORDERSActa Medica Scandinavica, 1975
- Treatment of chronic lymphocytic leukemia and lymphosarcoma with a new chlorambucil ester of prednisolone (Leo 1031) (NSC-134087)Journal of Surgical Oncology, 1975
- Cell killing effectiveness of an alkylating steroid (Leo 1031)Published by Elsevier ,1973